PharmaResearch and VIVACY Forge Strategic Partnership for Rejuran Distribution in Europe

PharmaResearch Partners with VIVACY for Rejuran Distribution

In a significant move for the aesthetic medicine industry, PharmaResearch, a South Korean leader in regenerative medicine, announced the signing of a strategic partnership with Laboratoires VIVACY, a renowned French aesthetic medical company. This collaboration aims to distribute PharmaResearch's acclaimed medical device, Rejuran, throughout Europe, tapping into VIVACY’s established market presence and reputation in the region.

Expanding Footprint in Europe

PharmaResearch's CEO, Jihoon Sohn, shared that this partnership is set to enhance the visibility and availability of Rejuran in key European markets including the UK, Germany, France, Italy, and Spain. The partnership encompasses a robust distribution network across 22 European countries, leveraging VIVACY's strong marketing and commercial capabilities. The projected value of the collaboration is approximately 54.5 million euros over five years, marking a significant investment in the European aesthetic market.

The Rejuran device is notable as it is the only medical device based on polynucleotides (PN) approved under the EU Medical Device Regulation (MDR). This unique status sets the stage for a successful entry into the competitive European market, where the demand for advanced skin enhancement solutions is rising.

Joining Forces for Market Leadership

The CEO of VIVACY, Bertrand, expressed confidence in the partnership, citing the premium brand positioning of Rejuran as a key factor in its potential success. He remarked, "The combination of Rejuran's demonstrated efficacy, high product quality, and VIVACY’s scientific reputation and marketing power creates the perfect recipe for a successful launch in Europe." This synergy may provide healthcare professionals with leading-edge polynucleotide technology, enhancing the aesthetic regeneration offerings available to patients.

Strengthening the Global Reach

This partnership is a concerted effort by both companies to expand their global reach while offering innovative and effective solutions for skin regeneration. PharmaResearch is committed to gradually implementing Rejuran throughout Europe starting this year, with ambitious plans to capture significant market share in the aesthetic sector.

The reputation of Laboratoires VIVACY as pioneers in regenerative aesthetics adds substantial credibility to the partnership. Founded in 2007, VIVACY specializes in premium medical devices using hyaluronic acid. The company is known for its pioneering products such as STYLAGE® and DESIRIAL®, which have already garnered a loyal following across over 85 countries.

A Vision for the Future

PharmaResearch focuses not only on medical devices but also boasts a diverse portfolio that includes pharmaceuticals, cosmetics, and supplements. Their patented technologies, such as DOT™ PDRN and DOT™ PN, position them as innovators in the field of regenerative medicine. This partnership with VIVACY is expected to strengthen PharmaResearch’s international footprint while delivering advanced solutions for aesthetics practitioners and their patients.

With combined expertise and dedication, the partnership represents a forward-thinking approach to developing and distributing regenerative medical solutions in Europe. As the market evolves, both companies are set to play pivotal roles in establishing Rejuran as a fixture in modern aesthetic treatments.

For more information about PharmaResearch, visit PharmaResearch and for VIVACY, explore VIVACY.